Moderna

Moderna has begun a Phase 1 clinical trial of an Ebola vaccine targeting the Zaire strain responsible for the outbreak in the Democratic Republic of the Congo. The trial marks the first human testing of the candidate, which uses the same mRNA technology behind Moderna's COVID-19 vaccine. Coverage is highlighting the company's growing pipeline and the urgent need for new Ebola countermeasures in central Africa.

The updated 2026-2027 COVID-19 vaccine rollout has begun in the United States, with people booking Moderna booster appointments at pharmacies such as Walgreens. The news comes as analysts report a 13th COVID wave underway, with outbreaks in 40 states and territories and roughly 3.8 million new infections, prompting calls for timely vaccination.